Article
Hematology
Kotaro Shide, Katsuto Takenaka, Akira Kitanaka, Akihiko Numata, Takuro Kameda, Takuji Yamauchi, Atsushi Inagaki, Shohei Mizuno, Akiyoshi Takami, Shinichi Ito, Masao Hagihara, Kensuke Usuki, Takaaki Maekawa, Kazutaka Sunami, Yasunori Ueda, Miyuki Tsutsui, Miki Ando, Norio Komatsu, Keiya Ozawa, Mineo Kurokawa, Shunya Arai, Kinuko Mitani, Koichi Akashi, Kazuya Shimoda
Summary: This study conducted a real-world survey to investigate the clinical characteristics and prognosis of patients with post-essential thrombocythemia myelofibrosis (PET-MF) and post-polycythemia vera myelofibrosis (PPV-MF) in the ruxolitinib era. The findings showed that PET-MF and PPV-MF patients had similar demographics, diagnosis times, and treatment approaches. The overall survival rates were also comparable between the two groups.
ANNALS OF HEMATOLOGY
(2023)
Review
Oncology
Rory M. Shallis, Nikolai A. Podoltsev
Summary: Both PV and ET are driven by JAK-STAT pathway activation, leading to recent research focusing on inhibiting this pathway to improve management and outcomes. New agents exploiting a growing understanding of PV and ET pathogenesis and disease evolution mechanisms are being developed, with potential to modify disease course and show clinical efficacy in patients.
BIOMARKER RESEARCH
(2021)
Article
Hematology
Christophe Nicol, Nadine Ajzenberg, Karine Lacut, Francis Couturaud, Eric Lippert, Brigitte Pan-Petesch, Jean-Christophe Ianotto
Summary: The incidence and risk factors of bleedings in patients with myeloproliferative neoplasms (MPNs) have been studied. Risk factors include abnormal white blood cell and platelet counts, history of bleeding, secondary hematological disorders, and secondary cancers.
THROMBOSIS AND HAEMOSTASIS
(2022)
Review
Hematology
Christophe Nicol, Karine Lacut, Brigitte Pan-Petesch, Eric Lippert, Jean-Christophe Ianotto
Summary: Hemorrhage is a common complication in essential thrombocythemia (ET) and polycythemia vera (PV), but there is a lack of evidence-based data on its management and prevention. This review analyzed data from the past 15 years regarding bleeding epidemiology, classification, location, and risk factors, highlighting the need for further research on bleeding risk factors in these diseases.
THROMBOSIS AND HAEMOSTASIS
(2021)
Article
Hematology
Guangshuai Teng, Yuan Zhou, Yuhui Zhang, Naibo Hu, Tong Liu, Yingdi Han, Chao Gao, Lei Zhang, Jie Bai
Summary: In patients with post-polycythemia vera myelofibrosis, the incidence of thrombosis is higher. Palpable splenomegaly, age above 60 years, and history of thrombosis are independent risk factors for thrombosis.
THROMBOSIS RESEARCH
(2022)
Review
Oncology
Douglas Tremblay, Heidi E. Kosiorek, Amylou C. Dueck, Ronald Hoffman
Summary: Thrombosis is a major cause of morbidity and mortality in patients with polycythemia vera and essential thrombocythemia. Current understanding of the risk factors and pathophysiology of thrombosis in these patients is growing, though few therapies have shown effectiveness in reducing thrombotic burden. More studies are needed to evaluate the impact of therapeutic agents on thrombotic events in these myeloproliferative neoplasms.
FRONTIERS IN ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Mattheus H. E. Wildschut, Julien Mena, Cyril Dordelmann, Marc van Oostrum, Benjamin D. Hale, Jens Settelmeier, Yasmin Festl, Veronika Lysenko, Patrick M. Schurch, Alexander Ring, Yannik Severin, Michael S. Bader, Patrick G. A. Pedrioli, Sandra Goetze, Audrey van Drogen, Stefan Balabanov, Radek C. Skoda, Massimo Lopes, Bernd Wollscheid, Alexandre P. A. Theocharides, Berend Snijder
Summary: In this study, we integrated ex vivo drug response and proteotype analyses to discover targetable vulnerabilities and associated therapeutic strategies for myelofibrosis patients. We identified three targetable vulnerabilities, including the sensitivity to BET and HDAC inhibitors driven by CALR mutations, the sensitivity to drugs targeting pro-survival signaling and DNA replication associated with an MCM complex-high proliferative signature, and the ER stress response in homozygous CALR mutations. Our findings provide a molecularly motivated roadmap for individualized treatment of myelofibrosis patients.
NATURE COMMUNICATIONS
(2023)
Article
Cardiac & Cardiovascular Systems
Seong Soon Kwon, Seug Yun Yoon, Sun Young Jeong, Min-Young Lee, Kyoung-Ha Kim, Namsu Lee, Jong-Ho Won
Summary: Patients with essential thrombocythemia (ET)/polycythemia vera (PV) show higher neutrophil-lymphocyte ratio (NLR) and carotid plaque burden compared to the normal population, indicating that PV/ET is a highly inflammatory and atherosclerotic condition with potentially increased cardiovascular risk.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
(2022)
Article
Multidisciplinary Sciences
Derek W. Brown, Weiyin Zhou, Youjin Wang, Kristine Jones, Wen Luo, Casey Dagnall, Kedest Teshome, Alyssa Klein, Tongwu Zhang, Shu-Hong Lin, Olivia W. Lee, Sairah Khan, Jacqueline B. Vo, Amy Hutchinson, Jia Liu, Jiahui Wang, Bin Zhu, Belynda Hicks, Andrew St Martin, Stephen R. Spellman, Tao Wang, H. Joachim Deeg, Vikas Gupta, Stephanie J. Lee, Neal D. Freedman, Meredith Yeager, Stephen J. Chanock, Sharon A. Savage, Wael Saber, Shahinaz M. Gadalla, Mitchell J. Machiela
Summary: The study identified 6 germline susceptibility loci and high frequencies of mosaic chromosomal alterations (mCAs) in myelofibrosis cases. The mCAs involving JAK2 were found to be strong promoters of clonal expansion in mutated clones of myelofibrosis cases.
NATURE COMMUNICATIONS
(2022)
Review
Hematology
Hannah Goulart, John Mascarenhas, Douglas Tremblay
Summary: This review discusses the complications and risk stratification methods in patients with myeloproliferative neoplasms (MPNs) polycythemia vera (PV) and essential thrombocythemia (ET). Current treatment options for low-risk patients are limited, but novel therapies are being investigated.
ANNALS OF HEMATOLOGY
(2022)
Review
Microbiology
Christina Schjellerup Eickhardt-Dalboge, Anna Cacilia Ingham, Henrik V. Nielsen, Kurt Fuursted, Christen Rune Stensvold, Lee O'Brien Andersen, Morten Kranker Larsen, Lasse Kjaer, Sarah Friis Christensen, Trine Alma Knudsen, Vibe Skov, Christina Ellervik, Lars Ronn Olsen, Hans Carl Hasselbalch, Jens Jorgen Elmer Christensen, Xiaohui Chen Nielsen
Summary: This study investigates the gut microbiota in patients with essential thrombocythemia (ET) and found that they have higher richness and different bacterial composition compared to healthy controls. The relative abundance of certain bacteria within the Firmicutes phylum is lower in ET patients, including an important immunoregulative bacterium Faecalibacterium. These findings suggest a potential role of gut microbiota in immune dysregulation of ET patients.
MICROBIOLOGY SPECTRUM
(2023)
Article
Oncology
Patryk Sobieralski, Bartosz Wasag, Aleksandra Leszczynska, Monika Zuk, Maria Bieniaszewska
Summary: This study demonstrates the dynamic nature of the molecular profile of patients with PV and ET through targeted next-generation sequencing. Specific variants were found to be associated with secondary myelofibrosis, thrombotic events, and treatment response. The limited utility of existing prognostic tools was also highlighted.
FRONTIERS IN ONCOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Jing Wu, YongZhen Fan, Wei Zhao, Bing Li, Naifan Pan, Zhiyang Lou, Mingyou Zhang
Summary: The study found that patients hospitalized with AMI and ET or polycythemia vera have an increased risk of adverse outcomes, particularly in terms of bleeding. A multidisciplinary approach is needed for the management of AMI to ensure patient safety and improve outcomes.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2022)
Article
Hematology
Andrew L. Sochacki, Cosmin Adrian Bejan, Shilin Zhao, Ameet Patel, Ashwin Kishtagari, Travis P. Spaulding, Alexander J. Silver, Shannon S. Stockton, Kelly Pugh, R. Dixon Dorand, Manasa Bhatta, Nicholas Strayer, Siwei Zhang, Christina A. Snider, Thomas Stricker, Aziz Nazha, Alexander G. Bick, Yaomin Xu, Michael R. Savona
Summary: Treatment decisions in primary myelofibrosis are usually determined by various prognostic systems, but they do not routinely incorporate patient-specific comorbidities. In this study, the impact of comorbidities on survival was assessed, and it was found that specific comorbidities were associated with inferior survival in primary myelofibrosis patients. By including comorbidities in the risk evaluation, the prognostic capability of genetics-based scoring systems could be enhanced.
Article
Cardiac & Cardiovascular Systems
Anna Weronska, Elzbieta Papuga-Szela, Elzbieta Broniatowska, Anetta Undas
Summary: This study indicates that NOACs may be effective and safe as secondary prevention of VTE in patients with myeloproliferative neoplasms, with no significant differences related to the type of NOAC. Recurrent thrombotic events and bleeding were observed, but overall mortality was low, suggesting potential benefits of NOAC use in this patient population.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
(2021)
Article
Hematology
Francesco Mannelli, Francesca Gesullo, Carmela Mannarelli, Fiorenza Vanderwert, Stefano Lazzi, Francesco Mungai, Valentina Berti, Raffaella Santi, Paola Guglielmelli, Alessandro M. Vannucchi
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Biophysics
Ryszard Swoboda, Myriam Labopin, Sebastian Giebel, Thomas Schroeder, Nicolaus Kroeger, Mutlu Arat, Bipin Savani, Alexandros Spyridonidis, Rose-Marie Hamladji, Victoria Potter, Ana Berceanu, Ibrahim Yakoub-Agha, Alessandro Rambaldi, Hakan Ozdogu, Jaime Sanz, Arnon Nagler, Mohamad Mohty
Summary: This study compared two different myeloablative conditioning regimens, FluTBI12 and FB4, before allo-HCT in AML patients. The results showed no significant differences in leukemia-free survival, overall survival, relapse incidence, and non-relapse mortality between the two groups. The incidence of acute and chronic GVHD also showed no statistical differences. In conclusion, FluTBI12 and FB4 are comparable myeloablative regimens for AML patients transplanted in CR1 and CR2.
BONE MARROW TRANSPLANTATION
(2023)
Article
Hematology
Annalisa Arcari, Valentina Tabanelli, Francesco Merli, Luigi Marcheselli, Michele Merli, Monica Balzarotti, Vittorio Ruggero Zilioli, Alberto Fabbri, Federica Cavallo, Gloria Margiotta Casaluci, Alessandra Tucci, Benedetta Puccini, Elsa Pennese, Alice Di Rocco, Manuela Zanni, Leonardo Flenghi, Guido Gini, Roberto Sartori, Annalisa Chiappella, Sara Veronica Usai, Monica Tani, Dario Marino, Luca Arcaini, Daniele Vallisa, Michele Spina
Summary: Up to 10%-15% of DLBCL cases in elderly patients are related to HCV infection. HCV+ patients were older, less fit, and had frequent extranodal involvement compared to HCV- patients. The use of DAAs in HCV+ patients showed good tolerance and a positive impact on progression-free survival.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Letter
Oncology
Paola Guglielmelli, Chiara Maccari, Benedetta Sordi, Manjola Balliu, Alessandro Atanasio, Carmela Mannarelli, Giulio Capecchi, Ilaria Sestini, Giacomo Coltro, Giuseppe Gaetano Loscocco, Giada Rotunno, Eva Angori, Filippo C. Borri, Ayalew Tefferi, Alessandro M. Vannucchi
BLOOD CANCER JOURNAL
(2023)
Letter
Hematology
Omer S. Karrar, Maymona Abdelmagid, Alessandro M. Vannucchi, Tiziano Barbui, Ayalew Tefferi, Naseema Gangat
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Francesca Arciprete, Paola Verachi, Fabrizio Martelli, Mauro Valeri, Manjola Balliu, Paola Guglielmelli, Alessandro Maria Vannucchi, Anna Rita Migliaccio, Maria Zingariello
Summary: Emperipolesis between neutrophils and megakaryocytes plays an important role in myelofibrosis. The challenge of studying this phenomenon by transmission electron microscopy has been overcome by the establishment of a user-friendly confocal microscopy method. Treatment with the inhibitor reparixin can reduce the emperipolesis between neutrophils and megakaryocytes. These findings identify neutrophil/megakaryocyte emperipolesis as the cellular interaction that links interleukin 8 to TGF-,B abnormalities in the pathobiology of marrow fibrosis.
EXPERIMENTAL HEMATOLOGY
(2023)
Letter
Hematology
Alessandro Atanasio, Sara Bernabini, Angela Consagra, Irene Giotti, Valentina Carrai, Elisabetta Pelo, Alessandro Maria Vannucchi
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Sara Fraticelli, Marco Lucioni, Giuseppe Neri, Deborah Marchiori, Caterina Cristinelli, Michele Merli, Rodolfo Monaco, Tiziana Borra, Antonio Lazzaro, Silvia Uccella, Luca Arcaini, Marco Paulli
Summary: Castleman disease (CD) is a rare lymphoproliferative disorder with various clinico-pathological subtypes. The pathogenesis of CD is still uncertain, but alterations in T-cell subsets may contribute to the development of CD. In this study, the distribution of T-cell subsets in the clinico-pathological spectrum of CD was investigated. The results showed decreased CD4/CD8 ratio and lower number of FOXP3+ T-reg cells in CD cases compared to non-specific reactive lymph nodes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Editorial Material
Oncology
William Shomali, Philomena Colucci, Tracy I. George, Jean-Jacques Kiladjian, Cheryl Langford, Jay L. Patel, Andreas Reiter, Alessandro M. Vannucchi, Jason Gotlib
Article
Oncology
Elisa Bianchi, Sebastiano Rontauroli, Lara Tavernari, Margherita Mirabile, Francesca Pedrazzi, Elena Genovese, Stefano Sartini, Massimiliano Dall'Ora, Giulia Grisendi, Luca Fabbiani, Monica Maccaferri, Chiara Carretta, Sandra Parenti, Sebastian Fantini, Niccolo Bartalucci, Laura Calabresi, Manjola Balliu, Paola Guglielmelli, Leonardo Potenza, Enrico Tagliafico, Lorena Losi, Massimo Dominici, Mario Luppi, Alessandro Maria Vannucchi, Rossella Manfredini
Summary: BM fibrosis is a major pathology in myelofibrosis and is associated with overexpression of OPN protein. ERK1/2 is a key regulator of OPN production, and inhibiting ERK1/2 activity can reduce OPN production and hinder the development of BM fibrosis. Targeting OPN and ERK1/2 could be potential therapeutic strategies for myelofibrosis.
Article
Hematology
Rami S. Komrokji, Luis E. Aguirre, Najla H. Al Ali, Onyee Chan, Zhuoer Xie, Andrew Kuykendall, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman
Article
Hematology
Hubert Schrezenmeier, Austin Kulasekararaj, Lindsay Mitchell, Regis Peffault de Latour, Timothy Devos, Shinichiro Okamoto, Richard Wells, Evan Popoff, Antoinette Cheung, Alice Wang, Ioannis Tomazos, Yogesh Patel, Jong Wook Lee
Summary: This study identifies LDH levels as an important determinant of fatigue and quality of life outcomes in patients with PNH.
ANNALS OF HEMATOLOGY
(2023)
Article
Hematology
Britta Hoechsmann, Regis Peffault de Latour, Anita Hill, Alexander Roeth, Timothy Devos, Christopher J. Patriquin, Wen-Chien Chou, Deepak Jain, Ke Zu, Chuntao Wu, Jong Wook Lee
Summary: The objective of this analysis was to identify risk factors for thromboembolic events (TE) in patients with paroxysmal nocturnal hemoglobinuria (PNH) who were not treated with C5 inhibitors. Multivariable analysis revealed that a history of TE, >= 30% GPI-negative granulocytes, and LDH ratio >= 1.5 x ULN with >= 2 high disease activity criteria are risk factors for TE in PNH patients.
ANNALS OF HEMATOLOGY
(2023)
Article
Hematology
Alexandre Theocharides, Heinz Gisslinger, Valerio De Stefano, Vincenzo Accurso, Alessandra Iurlo, Timothy Devos, Miklos Egyed, Eric Lippert, Regina Garcia Delgado, Nathan Cantoni, Anders E. A. Dahm, Damianos Sotiropoulos, Erik Houtsma, Aoife Smyth, Amir Iqbal, Paola Di Matteo, Mike Zuurman, Peter A. W. te Boekhorst
Summary: This study demonstrates that ruxolitinib treatment in patients with polycythemia vera who are resistant and/or intolerant to hydroxyurea maintains durable hematocrit control, reduces the need for phlebotomies, and is generally well tolerated.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Nicola Stefano Fracchiolla, Mariarita Sciume, Cristina Papayannidis, Antonella Vitale, Sabina Chiaretti, Mario Annunziata, Fabio Giglio, Prassede Salutari, Fabio Forghieri, Davide Lazzarotto, Monia Lunghi, Annalisa Imovilli, Barbara Scappini, Massimiliano Bonifacio, Michelina Dargenio, Carmela Gurrieri, Elisabetta Todisco, Marzia Defina, Maria Ilaria Del Principe, Patrizia Zappasodi, Marco Cerrano, Lidia Santoro, Elena Tagliaferri, Enrico Barozzi, Pasquale De Roberto, Marta Canzi, Elisa Buzzatti, Chiara Sartor, Francesco Passamonti, Robin Foa, Antonio Curti, Thomas Wirth
Summary: This retrospective study evaluated the efficacy and safety of blinatumomab and inotuzumab ozogamicin in the treatment of relapsed B-lymphoblastic leukemia. The study demonstrated the feasibility and effectiveness of sequential immunotherapy using these two drugs in terms of minimal residual disease, overall survival, and disease-free survival.
